JPWO2020132504A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020132504A5 JPWO2020132504A5 JP2021535679A JP2021535679A JPWO2020132504A5 JP WO2020132504 A5 JPWO2020132504 A5 JP WO2020132504A5 JP 2021535679 A JP2021535679 A JP 2021535679A JP 2021535679 A JP2021535679 A JP 2021535679A JP WO2020132504 A5 JPWO2020132504 A5 JP WO2020132504A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- independently hydrogen
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024094279A JP2024107296A (ja) | 2018-12-21 | 2024-06-11 | ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862784222P | 2018-12-21 | 2018-12-21 | |
| US201862784229P | 2018-12-21 | 2018-12-21 | |
| US62/784,222 | 2018-12-21 | ||
| US62/784,229 | 2018-12-21 | ||
| PCT/US2019/067953 WO2020132504A1 (en) | 2018-12-21 | 2019-12-20 | 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024094279A Division JP2024107296A (ja) | 2018-12-21 | 2024-06-11 | ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022514385A JP2022514385A (ja) | 2022-02-10 |
| JPWO2020132504A5 true JPWO2020132504A5 (enrdf_load_stackoverflow) | 2022-11-18 |
| JP7692830B2 JP7692830B2 (ja) | 2025-06-16 |
Family
ID=69591712
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535679A Active JP7692830B2 (ja) | 2018-12-21 | 2019-12-20 | ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物 |
| JP2024094279A Pending JP2024107296A (ja) | 2018-12-21 | 2024-06-11 | ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024094279A Pending JP2024107296A (ja) | 2018-12-21 | 2024-06-11 | ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物 |
Country Status (12)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013112605A2 (en) | 2012-01-23 | 2013-08-01 | Sage Therapeutics, Inc. | Neuroactive steroid formulations and methods of treating cns disorders |
| BR112015003747A2 (pt) | 2012-08-21 | 2017-07-04 | Sage Therapeutics Inc | métodos de tratamento de epilepsia ou estado de mal epiléptico |
| IL310348A (en) | 2013-04-17 | 2024-03-01 | Sage Therapeutics Inc | 19- NOR C3, 3- dimomer C21- N- pyrazole Steroids and methods of using them |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| ES2793237T3 (es) | 2014-11-27 | 2020-11-13 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| US11236121B2 (en) | 2016-08-23 | 2022-02-01 | Sage Therapeutics, Inc. | Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| CN113383004A (zh) | 2018-12-05 | 2021-09-10 | 萨奇治疗股份有限公司 | 神经活性类固醇及其使用方法 |
| WO2021262836A1 (en) * | 2020-06-24 | 2021-12-30 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof |
| CN119192275B (zh) * | 2024-08-22 | 2025-05-30 | 湖南玉新药业有限公司 | 一种3-羰基-4-氮杂-5α-雄甾-17β-羧酸化合物的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| CA3152410A1 (en) | 2011-10-14 | 2013-04-18 | Sage Therapeutics, Inc. | 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders |
| US9512170B2 (en) * | 2013-03-01 | 2016-12-06 | Washington University | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors |
| CN118344423A (zh) | 2014-10-16 | 2024-07-16 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| DK3258939T3 (da) | 2015-02-20 | 2022-12-12 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser heraf |
| US11396525B2 (en) * | 2016-07-11 | 2022-07-26 | Sage Therapeutics, Inc. | C17, C20, and C21 substituted neuroactive steroids and their methods of use |
-
2019
- 2019-12-20 BR BR112021012242-7A patent/BR112021012242A2/pt unknown
- 2019-12-20 US US17/416,367 patent/US20220372067A1/en active Pending
- 2019-12-20 WO PCT/US2019/067953 patent/WO2020132504A1/en active IP Right Grant
- 2019-12-20 TW TW108147086A patent/TWI848034B/zh active
- 2019-12-20 MX MX2021007504A patent/MX2021007504A/es unknown
- 2019-12-20 AU AU2019403415A patent/AU2019403415B2/en active Active
- 2019-12-20 CA CA3124371A patent/CA3124371A1/en active Pending
- 2019-12-20 KR KR1020217022533A patent/KR20210107050A/ko active Pending
- 2019-12-20 CN CN201980085054.3A patent/CN113195512A/zh active Pending
- 2019-12-20 EP EP19850836.8A patent/EP3898646A1/en active Pending
- 2019-12-20 JP JP2021535679A patent/JP7692830B2/ja active Active
-
2021
- 2021-06-18 MX MX2025000126A patent/MX2025000126A/es unknown
- 2021-06-20 IL IL284183A patent/IL284183A/en unknown
-
2024
- 2024-06-11 JP JP2024094279A patent/JP2024107296A/ja active Pending